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Introduction 
The COVID-19 pandemic has had dramatic effects on worldwide healthcare systems, and its 
psychiatric and neuropsychiatric effects have been well documented in the general 
population(Rogers et al., 2020) and in specific populations such as healthcare 
workers(Salazar de Pablo et al., 2020). Globally, intense pressures on inpatient beds in the 
acute physical health setting have had a knock-on effect on mental health pathways and 
provision, with mental health provider organisations sometimes temporarily shutting selected 
community services, including Early Intervention for Psychosis (EI) teams. EI services 
encompass First-Episode of Psychosis (FEP) services (Correll et al., 2018) for those with a 
first onset illness and Clinical High Risk for Psychosis services (CHR-P) for young individuals 
with subtle symptoms of the disorder (Catalan et al., 2020; Fusar-Poli et al., 2020b). This 
report draws on twenty-years’ clinical experience gained by EI services in South London and 
Maudsley NHS Trust (established in 2001)(Fusar-Poli et al., 2020a; Fusar-Poli et al., 2020c) 
to provide four pragmatic recommendations for EI services during the COVID-19 pandemic. It 
should be noted that EI services are targeted at people with severe mental disorders, who are 
at higher risk of needing acute psychiatric care, including hospitalisation.  
 
Recommendation 1 
EI services for psychosis should prepare for an increase in activity because of the potentially 
higher risk of psychosis during the COVID-19 pandemic 
The COVID-19 pandemic is likely to lead to an increased incidence of psychosis, via three 
potential mechanisms. 
1.1 As pointed out in a recent review (Kępińska et al., 2020), the association between 
viruses such as influenza and symptoms of major mental illness has been recognised as far 
back as 1732. The clearest illustration of a putative relationship remains the Spanish influenza 
epidemic of 1918-19, Menninger reporting data on patients admitted over a 3 month period to 
the Boston Psychopathic Hospital, finding 25 of 80 people admitted acutely following influenza 
fulfilling criteria for dementia praecox (i.e. a narrow Kraepelinian definition of non-affective 
psychosis), as opposed to delirium and other psychoses (Menninger, 1919). Notably, further 
studies of 175 people with post-influenza psychoses at the same hospital indicated 50 cases 
of dementia praecox, followed up for one to five years, indicated a significant proportion (35) 
were noted to have a complete recovery, 5 to have some improvement, 5 no change, and 5 a 
worsening of their condition. The length of symptoms and clinical case presentations counts 
against these cases being ascribed to a prolonged delirium (Menninger, 1926). In the early 
weeks of the COVID-19 epidemic in London, we have observed a suspected increase of cases 
of psychotic disorders in our healthcare system-in particular among middle-age men-currently 
under investigation, and which contrasts with the equal sex distribution seen in our catchment 
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area. This would also suggest that EI services during COVID-19 pandemic may relax entry 
age criteria (worldwide these are typically restricted to 14-35 years), in keeping with recent 
Department of Health guidance (Chandra et al., 2018), to allow early detection and treatment 
of psychosis onset in older individuals. 
1.2 Examination of factors related to the current pandemic points to increased cumulative 
risk for the development of psychotic disorders. These factors include, but are not restricted, 
to those contributing to the incidence of the current infection (urban environment), those 
related to necessary interventions, e.g. social distancing (social fragmentation and 
loneliness(Smith and Lim, 2020)), and general factors related to the pandemic, such as social 
isolation, which contribute to social inequalities, in particular in vulnerable groups (see below). 
It is clear that the infection is more likely to occur in urban environments, and these are already 
associated with increased risk of psychosis at least in Northern Europe, with an odds ratio of 
2.19 (95% CI 1.55-3.09) (Radua et al., 2018). Social fragmentation (a prerequisite of social 
distancing, one of the main public health interventions in the current pandemic) has 
detrimental effects on mental health (Brooks et al., 2020). Social isolation increases the risk 
of psychosis, with an odds ratio of 12.8 (95% CI 5.71-28.88) in the most fragmented area 
compared to the least fragmented (Allardyce et al., 2005). This effect appears to exist 
irrespective of rural or urban environment. Added to this should be the general risk conferred 
by psychosocial stress, life events, including trauma (Radua et al., 2018). 
1.3 Third, these effects may be more pronounced in ethnic minorities, homeless people 
and immigrants, which are all independent risk factors for psychosis (Pareek et al., 2020). 
Recent evidence indicates the COVID-19 pandemic is particularly severe in ethnic minorities, 
which are highly represented in populations accessing EI services. CHR-P services are ideally 
placed to investigate the contributions of various risk factors to psychosis(Oliver et al., 2020) 
in the context of COVID-19 (Kotlicka-Antczak et al., 2020). These services are also 
engineered to improve early detection and may contribute to address the possible increase in 
COVID-19 related incidence of psychosis. For example, these services are designed to take 
care of patients with short-lived psychotic episodes (e.g. Brief and Limited Intermittent 
Psychotic Symptoms, which overlap with Acute and Transient Psychotic Disorders or Brief 
Psychotic Disorders)(Fusar-Poli et al., 2016; Fusar-Poli et al., 2017a; Fusar-Poli et al., 2019). 
Several studies indicate that short-lived psychotic episodes are an emerging clinical 
phenomenon of the COVID-19 pandemic(D. Agostino et al., 2021; Valdes-Florido et al., 2020).  
 
Recommendation 2 
FEP services should increase their focus on early interventions and relapse prevention to 
reduce hospital admissions 
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Whilst EI services were originally conceptualised to decrease the duration of untreated 
psychosis during a FEP, and therefore improve functioning, over the years they have also 
increasingly focused on relapse prevention (Taylor and Jauhar, 2019). 
2.1 This has particular relevance for the current COVID-19 pandemic, as relapses 
constitute a significant proportion of readmissions to hospital (Taylor and Jauhar, 2019). The 
literature on the natural history of non-affective psychotic illness (including in the pre-
antipsychotic era) suggests that interventions given during the first five years are more likely 
to impact on short and longer-term outcomes (Fusar-Poli et al., 2017b). These interventions 
include antipsychotic treatment, intensive care coordination, and psycho-social interventions, 
which constitute the core components of an EI service. The most recent systematic review 
and meta-analysis concluded that EI substantially decreased risk of relapse (RR, 0.71; 95% 
CI= 0.53-0.93) (Correll et al., 2018). 
2.2 Around 15% of people within EI services fulfil criteria for bipolar disorder, and many 
people with first-episode mania come into contact with EI services (Jauhar et al., 2019). These 
patients are even more likely to be hospitalised than those with first-episode schizophrenia-
like psychosis (Chang et al., 2016), and EI services are well placed to reduce their risk of 
hospitalisation. In the absence of EI services, it is unclear which services will effectively cater 
to this population and prevent relapse. 
2.3 EI services have played a psychoeducational role in the management of substance 
misuse, specifically cannabis misuse, a significant predictor of relapse. This has relevance to 
the current pandemic, as people continue to have access to substances, and relapses in this 
context are likely, and possibly amenable to treatment. 
2.4 Lastly, continuity of care and approach is fundamental to keeping patients engaged in 
treatment. EI services are characterised by this approach. By reconfiguring EI teams and 
reducing continuity of care due to the current pandemic there is the possibility of decreased 
engagement with services, and stopping treatment, which is the major cause of relapse, in a 
population of people whose illness have a high risk of relapse (MacDonald et al., 2018). For 
example, up to 50% of individuals with an initial brief psychotic episode under the care of 
CHR-P services are at risk of relapse into persistent psychosis (Fusar-Poli et al., 2016). 
Therefore, focusing on routine work (including treatment of co-morbid substance misuse), as 
well as dealing with new incident cases is essential. 
 
Recommendation 3 
Refine physical health guidelines to improve outcomes in EI patients during the COVID-19 
pandemic. 
Psychotic disorders are frequently associated with physical co-morbidities, which reduce life 
expectancy. Specifically, these include vitamin D deficiency, the metabolic syndrome, 
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diabetes, cigarette smoking and general effects of psychotropic medication offered to this 
population. Therefore EI services adhere to specific standards for physical health (Chandra et 
al., 2018), as well as general considerations, which should be refined to meet the COVID-19 
circumstances. 
3.1 The need for face-to-face physical health checking should be considered on a case by 
case basis, with a risk-benefit analysis. To reduce the length of face-to-face examinations, we 
also recommend collecting remotely personal/family history for physical health illnesses, 
lifestyle review and weight checks. Appointments between patients should also be carefully 
scheduled to facilitate social distancing and avoid prolonged waiting periods in common areas. 
Any existing or emergent physical health co-morbidities associated with a greater risk of 
COVID-19 complications: diabetes, obesity, hypertension, cardiovascular and respiratory 
disease should be identified and managed, in collaboration with primary care, with appropriate 
shielding advice and arrangements put in place. 
3.2 EI patients are three times more likely to have vitamin D deficiency than their peers 
(Crews et al., 2013), and this can be worsened by prolonged lockdowns. There is evidence 
that vitamin D supplementation enhances the function of the immune system and reduces the 
risk of developing respiratory infections (Martineau et al., 2017). EI services in the SLaM NHS 
Trust have recently recommended short-term top-up vitamin D supplementation for working-
age adult in-patients without contraindications: community EI services are better placed to 
offer longer-term supplementation strategies. 
3.3 The role of cigarette smoking. Assisting EI patients with smoking cessation is 
particularly important during the COVID epidemic. EI clinicians should assume that smoking 
habits would reduce to some extent in-patients with COVID-19 related respiratory infections 
and stop with associated hospital admission. Dose reductions should, therefore, be 
considered with drugs that may be influenced by smoking: olanzapine, fluvoxamine, 
duloxetine, fluphenazine, benzodiazepines, tricyclic antidepressants, haloperidol, and 
carbamazepine (clozapine is covered in more depth below). 
3.4 The role of early weight gain and development of the metabolic syndrome in early 
psychosis is readily acknowledged. During the pandemic there will be increased propensity 
for weight gain in this population, given the decreased level of activity seen in the general 
population. Therefore monitoring of weight, which can be done remotely, is recommended, 
and thought in regard to psychotropic medication as well as lifestyle factors (diet and exercise, 
within the home) would seem reasonable measures. 
3.5 Most psychotropic drugs and some medications used to treat COVID-19, such as 
antimicrobials, antimalarials, and antiretrovirals, are associated with increased risk of 
prolonging QTc (in addition to the risk conferred by antipsychotics, with the exception of 
aripiprazole, cariprazine, lurasidone and paliperidone which appear to have negligible effects), 
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putting EI patients at higher acute and longer-term risk of life-threatening ventricular 
arrhythmias. Therefore, a repeat electrocardiogram should be considered. Furthermore, 
thought should also be given to possible interactions between psychotropic medication and 
putative treatments for COVID-19(Bishara et al., 2020). 
3.6 COVID-19 related symptoms should be distinguished from neuroleptic malignant 
syndrome (NMS), especially in the case of autonomic instability, fever, dyspnoea, and change 
in the level of consciousness, though we acknowledge rates of potential misdiagnosis are 
unknown. This is relevant to EI as a risk factor for NMS is recent initiation of a new neuroleptic 
drug, A thorough physical examination combined with a rapid COVID-19 antigen test is 
paramount to exclude the presence of severe muscle rigidity and/or autonomic instability. 
3.7 COVID-19 symptoms in patients taking clozapine can be difficult to distinguish from 
myocarditis. This has relevance for EI as it occurs more commonly in the first 1-2 months from 
initiation , and neutropenic sepsis occurs more often in the first year. After that period, a 
possible extension of full blood count monitoring could be considered. In the UK, those taking 
clozapine with fever are advised to be immediately tested for both agranulocytosis and 
coronavirus, especially when they also suffer from coughing, sore throat, shortness of breath 
and a runny nose. Moreover, in those patients with COVID-19 infection, clozapine dose should 
be decreased, by about 25% in those at high risk of relapse, with monitoring (Siskind et al., 
2020). Where a low white cell count occurs in the presence of a normal neutrophil level in the 
context of COVID-19 infection, it is thought that clozapine can be safely continued(Bishara et 
al., 2020). 
3.8 In EI patients taking lithium we emphasise general measures, such as need to maintain 
good fluid intake, particularly if they have fever, vomit or diarrhoea, and maintain lithium use 
if flu-like symptoms occur (with monitoring of lithium and electrolyte levels, as in general care). 
 
Recommendation 4 
Embed e-Health technology in the detection, assessment and care of EI patients 
eHealth approaches have high levels of patient satisfaction and acceptability in-patients with 
chronic illnesses, as well as their carers. In response to the COVID-19 pandemic, e-mental 
health can be particularly helpful as it can prevent exposure to additional unnecessary human 
contact and reduce emergency department overuse (Moazzami et al., 2020). 
4.1 We recommend reducing face-to-face contacts during lockdowns and introducing, 
whenever possible, virtual contacts during EI clinical care. EI patients (FEP and CHR-P 
individuals) are typically young and usually highly engaged with the digital world (Reilly et al., 
2019). There is no substantial evidence of EI patients having difficulties with 
videoconferencing or experiencing any exacerbation of symptoms because of it (Reilly et al., 
2019). In fact, most individuals in EI services are concordant with e-Health technologies, and 
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it should be acknowledged that younger people are more likely to have smartphones and 
embrace new technologies. 
In some young people, physical distance may actually relieve anxiety and concerns 
associated with attending appointments. In acute exacerbations or new transitions to 
psychosis from a CHR-P state, face-to-face care and in-person visits may be irreplaceable. 
Similarly, adherence to treatments should be monitored with additional caution to avoid loss 
to follow-up during virtual assessments, which may result in relapses. 
4.2 EI services can take advantage of the COVID-19 pandemic to fully implement virtual 
working policies. Our EI healthcare system is effectively digitised and paper-free, and it is a 
legal requirement for EI healthcare professionals to keep the local Electronic Health Record 
(EHR) up to date. The local EHR contains the full clinical records of all patients, which are 
continually updated throughout their care, regardless of discharges from and/or referrals to 
other services. The EHR can be accessed remotely by EI clinicians via virtual protected 
network access, thus respecting local and national confidentiality and privacy policies. The 
local EHR also allows embedding virtual conferencing platforms that are NHS-compliant for 
roll-out to EI staff, further facilitating working from home and communicating between patients 
and medical professionals. 
4.3 We also recommend exploring the availability of e-Health therapeutic approaches. For 
example, there is evidence that e-cognitive behavioural therapy (which is the first-line 
treatment in CHR-P patients) has similar effect sizes to face-to-face interventions across 
psychiatric disorders. Additionally, vocational interventions lend themselves well to digital 
technology and can be implemented easily during periods of lockdown. Therefore, the use of 
e-Health technology could be seen not only as a means of facilitating care. During the 
pandemic, but also a way of expanding future services for this patient group, building on the 
experience during the pandemic.  
 
Recommendation 5 
Prioritising EI patients in the vaccination campaign 
5.1  On December 2020, European Medicines Agency has approved the first COVID-19 
vaccine for authorisation across the European Union, inspiring hope in the face of future waves 
of the pandemic. The European Union advises prioritising for vaccination “persons whose 
state of health makes them particularly at risk” for severe COVID-19, but leaves it to member 
states to decide which medical conditions to prioritise. Although several countries have 
initiated their vaccination plans, only a few national vaccine strategy documents explicitly 
mentioned people with severe mental disorders such as those under the care of EI services. 
In light of the physical health burden and associated risk, we recommend that EI patients are 
prioritises during vaccination COVID-19 exit strategies. Tailored pandemic management and 
Jauhar S et al 2020 Version 2.0       27.01.21 
 8 
vaccination optimization and monitoring plans need to be created to cater to this group as an 
immediate public health priority and correct any intolerable inequality (De Picker et al., 2021). 
 
Conclusions 
In summary, the challenges posed by the COVID 19 pandemic, highlight the importance of EI 
services, which play a central role in the care of a particularly vulnerable patient group and 
decrease the burden on already stretched generic mental health systems. Consideration can 
be given to these recommendations by policymakers, service planners and commissioners, 
and those who provide mental health care. 
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